Open both boxes side by side and you cannot tell them apart. Same active molecule. Same single-dose autoinjector pen. Same 2.5 mg → 15 mg titration ladder. Both manufactured by Eli Lilly at the same facilities. The only physical difference is the color of the carton and the name printed on the label. Yet at most US pharmacies in 2026, one is billed at roughly $1,069 a month and the other at roughly $1,060, and after insurance routes them down completely separate pathways, the price you actually pay can swing by thousands of dollars per year based purely on which name your doctor wrote on the prescription pad.
This is not a manufacturing story. It is a labeling story, a regulatory story, and most of all an insurance-billing story. Once you understand how it works, the entire US weight-loss medication market starts to make a lot more sense — and a lot less.
The two drugs are chemically identical
Mounjaro and Zepbound are both tirzepatide — a synthetic peptide that activates two gut hormones (GLP-1 and GIP) at once. Eli Lilly synthesized the molecule, ran the clinical trials, manufactures it, and holds the patent. There is no second factory, no different formulation, no rebranded generic.
The pen is the same KwikPen-style single-dose injector. The strengths are the same: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The dosing schedule is the same — once weekly, subcutaneous injection. The titration protocol is the same — start at 2.5 mg for four weeks, increase as tolerated. The side-effect profile is the same. The contraindications are the same. The pharmacokinetics are the same.
If a pharmacist handed you a Mounjaro pen and a Zepbound pen of the same dose with the cartons removed, no laboratory test could distinguish them. They are the same product.
Why FDA gave the same molecule two labels
The FDA does not approve molecules. The FDA approves indications — specific clinical uses, supported by specific clinical trials, for specific patient populations. A drug company that wants to market a single molecule for two different conditions has to run two separate trial programs and file two separate applications, and the agency assigns each a separate brand name to keep the labeling and marketing distinct.
That is exactly what happened here. Eli Lilly first ran the SURPASS trial program for type 2 diabetes. Tirzepatide was approved as Mounjaro in May 2022 for adults with type 2 diabetes, with the indication "as an adjunct to diet and exercise to improve glycemic control."
Lilly then ran the SURMOUNT trial program for obesity. The same molecule was approved again in November 2023 — this time as Zepbound, indicated for "chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity."
Two indications. Two trial programs. Two approvals. Two brand names. One drug.
2026 list prices, side by side
The wholesale acquisition cost (WAC) — the published "list price" before any rebates, coupons, or insurance — looks like this in 2026:
| Product | Indication | Pen format | Monthly WAC |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | 4-pack autoinjector pens | $1,069.08 |
| Zepbound (pen) | Obesity / weight management | 4-pack autoinjector pens | $1,086.37 |
| Zepbound (vial, LillyDirect) | Obesity / weight management | Single-dose vials, self-pay | $499 – $649 |
That third row is the first crack in the wall: Eli Lilly directly sells the same molecule, in vial form, for less than half the pen WAC, through its LillyDirect self-pay channel. We will return to that.
The insurance fork: where the gap appears
Here is the point that almost nobody outside of pharmacy benefits explains clearly: commercial insurance plans treat diabetes drugs and obesity drugs in completely different ways.
Type 2 diabetes is a covered condition under essentially every commercial plan and every Medicare Part D plan in the United States. When a prescription for Mounjaro arrives at the pharmacy with a diabetes diagnosis attached, the insurance pathway is well-worn: the plan typically pays the bulk of the cost, the patient pays a copay (often $25 to $150 a month with a manufacturer savings card), and the rebate flow between Lilly and the pharmacy benefit manager (PBM) absorbs the rest.
Obesity, however, is treated by most commercial plans as a lifestyle rather than a covered medical condition. As of 2026, somewhere between 40% and 50% of commercial plans exclude weight-loss medications outright. Medicare Part D is statutorily prohibited from covering drugs used for "weight loss" — a holdover from the Medicare Modernization Act of 2003 that has not been changed despite multiple legislative attempts. State Medicaid programs are a patchwork: a minority cover Zepbound, most do not.
So when a Zepbound prescription with an obesity diagnosis hits the pharmacy, there is roughly a coin-flip chance that insurance simply rejects it. Patients are then quoted the full WAC of about $1,086 a month — and that is where the $13,000-a-year sticker shock stories come from.
Two patients walk into the same pharmacy on the same day. One is prescribed Mounjaro for diabetes; the other is prescribed Zepbound for obesity. They both have the same insurance plan. The diabetes patient pays $25. The obesity patient is told the prescription costs $1,086 cash. Same drug. Same plan. Different billing code.
LillyDirect self-pay and the $499 vials
Eli Lilly understands the obesity-coverage problem perfectly well — it costs them sales every time a Zepbound prescription is rejected and the patient gives up. Their answer in 2024, expanded throughout 2025, was the LillyDirect self-pay program: single-dose vials of Zepbound sold directly to patients, by mail, at fixed cash prices that bypass the insurance maze entirely.
As of 2026 the LillyDirect tiers run roughly:
| Dose | Format | Self-pay price |
|---|---|---|
| 2.5 mg / week | 4 single-dose vials | $349 |
| 5 mg / week | 4 single-dose vials | $499 |
| 7.5 mg / week | 4 single-dose vials | $599 |
| 10 mg / week | 4 single-dose vials | $649 |
This is real, brand-name Zepbound — same FDA-approved tirzepatide, same Lilly factory — at less than half the pharmacy pen price. The catch is that you draw and inject from a vial yourself rather than using the pre-filled pen, which a lot of patients find more intimidating but is functionally identical to how every diabetes patient has used insulin for fifty years.
If you have insurance that covers Zepbound, the pen route through your pharmacy is still cheaper at the copay level. If you do not have coverage, LillyDirect vials are the most affordable brand-name route on the market — and the program now ships in all 50 states.
The compounded tirzepatide alternative
The compounding pathway is more complicated, but for many uninsured patients in 2026 it is still the most affordable route to tirzepatide. 503A and 503B compounding pharmacies in the United States can produce tirzepatide formulations under specific FDA conditions — and during the FDA's official tirzepatide shortage (which ran from late 2022 through late 2024), they did so at scale.
The FDA officially declared the tirzepatide shortage resolved in October 2024, which technically narrows the legal basis for mass compounding. However, personalized prescriptions — formulations that include B12, glycine, or other additives, or that are tailored to a specific patient's clinical needs — remain a legitimate compounding pathway under section 503A. As of 2026 a substantial telehealth ecosystem still operates within this framework, with pricing typically running:
| Source | Format | Monthly cost |
|---|---|---|
| Compounded tirzepatide (telehealth) | Multi-dose vial | $179 – $399 |
| Brand Zepbound (LillyDirect vial) | Single-dose vials | $349 – $649 |
| Brand Zepbound (pen, no insurance) | 4-pack autoinjector | $1,086 |
Patients should weigh compounded versus brand-name carefully. Compounded products are not FDA-approved as finished drugs (they are prepared by licensed pharmacies under prescription) and quality varies between providers. Reputable telehealth companies use 503B-registered outsourcing facilities or established 503A pharmacies with documented sourcing and sterility programs.
For a deeper breakdown of the per-vial economics, see our companion piece: Tirzepatide Math: Why One Vial Costs $179 and the Same Drug at the Pharmacy Costs $1,069.
Which one should you actually ask for?
The honest answer is that this is a clinical question your prescriber decides — but understanding the billing implications can save you a lot of money and grief.
If you have type 2 diabetes: Mounjaro is the labeled product. Insurance will almost certainly cover it (subject to prior authorization). You will likely pay $25 to $150 per month with a manufacturer savings card. There is rarely any reason to ask for Zepbound instead.
If you have obesity (BMI ≥ 30) or overweight with comorbidities (BMI ≥ 27): Zepbound is the labeled product. The first thing to check is whether your specific plan covers Zepbound at all — many do not. If your plan covers it, you will pay a copay similar to a diabetes patient. If your plan does not, your three real options are (1) pay the $1,086 pharmacy cash price, (2) use the LillyDirect $349–$649 self-pay vial program for brand-name Zepbound, or (3) use a compounded tirzepatide route through a telehealth provider for $179–$399.
Do not ask your doctor to write Mounjaro for weight loss to "trick" insurance. This is off-label prescribing of a diabetes drug for obesity, and pharmacies and PBMs increasingly catch and reject these prescriptions. It can also create chart problems for your doctor. Use the labeled drug for the labeled indication, and choose your payment route accordingly.
The bottom line
Mounjaro and Zepbound are the same drug wearing two different uniforms. The price gap you see at the pharmacy is not a manufacturing gap — it is an insurance-coverage gap, a regulatory-history gap, and a marketing-channel gap. Once you understand which uniform you are buying and why your insurance treats it the way it does, the entire US tirzepatide market becomes navigable.
If you are paying full price for either one, you almost certainly have a cheaper legitimate route available. The companion articles in this series walk through every one of them.